Altimmune (ALT) director makes open-market share purchase

Rhea-AI Filing Summary

Altimmune, Inc. director John Gill reported an open-market purchase of 9,200 shares of common stock at a weighted average price of $3.4076 per share. After this transaction, he directly owns 21,700 Altimmune shares. The shares were bought in multiple trades between $3.4050 and $3.4080.

Insider Trade Summary

Net Buyer: 9,200 shares ($31,350)

Net Buy 1 txn

Insider GILL JOHN

Role Director

Bought 9,200 shs ($31K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001	9,200	$3.4076	$31K

Holdings After Transaction: Common Stock, par value $0.0001 — 21,700 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 9,200 shares Weighted average price: $3.4076 per share Price range: $3.4050–$3.4080 per share +1 more

4 metrics

Shares purchased 9,200 shares Open-market purchase on 2026-04-06

Weighted average price $3.4076 per share Price for 9,200 shares purchased

Price range $3.4050–$3.4080 per share Range of individual trade prices

Shares owned after trade 21,700 shares Direct ownership following the purchase

Key Terms

open-market purchase, weighted average price, Form 4

3 terms

open-market purchase financial

"transaction_action": "open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILL JOHN

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MARYLAND 20878

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	04/06/2026		P		9,200	A	$3.4076(1)	21,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4050 to $3.4080, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

	/s/ Gregory Weaver, as Attorney-in-Fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Altimmune (ALT) disclose in this Form 4?

Altimmune reported that director John Gill executed an open-market purchase of 9,200 common shares. The weighted average price was $3.4076 per share, and the trade was completed in multiple transactions on the same date.

How many Altimmune (ALT) shares does John Gill hold after this trade?

Following the reported purchase, John Gill directly holds 21,700 shares of Altimmune common stock. This total reflects his position after acquiring 9,200 shares in the open market at a weighted average price of $3.4076 per share.

At what price did John Gill buy Altimmune (ALT) shares?

John Gill’s Altimmune share purchase was executed at a weighted average price of $3.4076 per share. According to the filing, individual trades occurred in a narrow range between $3.4050 and $3.4080 inclusive during the same trading session.

Was the Altimmune (ALT) insider trade an open-market purchase?

Yes. The Form 4 classifies John Gill’s transaction as an open-market purchase of common stock. This means he bought shares on the market rather than receiving them as a grant, award, or option exercise from the company.

What does the weighted average price mean in the Altimmune (ALT) Form 4?

The weighted average price of $3.4076 reflects multiple trades executed between $3.4050 and $3.4080. The filing notes the insider will provide details on the number of shares bought at each specific price within that range upon request.